SANTA CLARA, Calif.--(BUSINESS WIRE)--Affymetrix Inc. (Nasdaq:AFFX) announced today that it is hosting two workshops at the third NCRI Cancer Conference in Birmingham, U.K. The ability to combine information from gene expression profiling, copy number alterations, loss of heterozygosity, alternative splicing and gene regulation is pivotal to understanding the molecular basis of cancer. The workshops will provide a forum for researchers and clinicians to learn about the latest technology advances from Affymetrix and to see examples of published cancer research studies that use integrated genomic approaches.
